


WHAT IS CLAIMED IS:

1. A compound having the structure of Formula (I) and acid-addition salts and pro-drug esters thereof:



wherein the ring structure is either not substituted or is substituted;

n is equal to 2, 3, or 4;

m is equal to 1, 2, or 3;

X and each separate X_n are each separately selected from is H, OH, OAc, NH₂ and halogen, and

wherein the dashed lines represent either a C-C bond or a C-H bond and the dashed and solid line represents either a C-C single bond or a C-C double bond.

2. The compound of Claim 1, wherein the ring structure is not substituted.
3. The compound of Claim 1, wherein the ring structure is mono-substituted.
4. The compound of Claim 1, wherein the ring structure is di-substituted.
5. The compound of Claim 1, wherein the substitution is selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C₁-C₂₄ alkyl, unsaturated C₁-C₂₄ alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-O-R₇, cyano, halogenated alkyl including polyhalogenated alkyl, and carbonyl -CCO-R₇, wherein R₇ is selected from a hydrogen atom, a halogen atom, and saturated C₁-C₂₄ alkyl, unsaturated C₁-C₂₄ alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups.


6. The compound of Claim 3, wherein the substitution is selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C₁-C₂₄ alkyl, unsaturated C₁-C₂₄ alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-O-R₇, cyano, halogenated alkyl including polyhalogenated alkyl, and carbonyl -CCO-R₇, wherein R₇ is selected from a hydrogen atom, a halogen atom, and saturated C₁-C₂₄ alkyl, unsaturated C₁-C₂₄ alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups.

7. The compound of Claim 4, wherein the substitution is selected from the group consisting of a hydrogen atom, a halogen atom, and saturated C₁-C₂₄ alkyl, unsaturated C₁-C₂₄ alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups, hydroxy, carboxy, -CO-O-R₇, cyano, halogenated alkyl including polyhalogenated alkyl, and carbonyl -CCO-R₇, wherein R₇ is selected from a hydrogen atom, a halogen atom, and saturated C₁-C₂₄ alkyl, unsaturated C₁-C₂₄ alkenyl, cycloalkyl, cycloalkenyl, alkoxy, cycloalkoxy, aryl, substituted aryl, heteroaryl, substituted heteroaryl, amino, substituted amino, nitro, azido, substituted nitro, phenyl, and substituted phenyl groups.

8. The compound of Claim 1, wherein n is equal to 3.

9. The compound of Claim 1, wherein the substitution comprises the substitution of a lower alkyl.

10. The compound of Claim 1, wherein the compound has the structure:



and acid-addition salts and its pro-drug esters.

11. A method of treating an individual with cancer, comprising:
administering to the individual a compound of Formula (I), its acid-addition salts and its pro-drug esters, or a composition comprising the compound of Formula (I) or its acid-addition salts and its pro-drug esters, wherein the compound is administered with a pharmaceutically acceptable carrier, diluent, or excipient.
12. A method of treating cancer comprising the step of contacting a cancer cell with a compound of Claim 1.
13. The method of Claim 12, wherein the cancer is a colon cancer.
14. The method of Claim 12, wherein the cancer is a prostate cancer.
15. The method of Claim 12, wherein the cancer is a leukemia.
16. The method of Claim 12, wherein the cancer is a melanoma cancer.
17. A method of treating cancer comprising contacting a patient diagnosed with cancer with a compound of Claim 1.